REDWOOD CITY, CA—Rose Geoffrey Beran, Chief Commercial Officer Pulmonx Corp (NASDAQ: ), recently sold stock in a number of transactions totaling approximately $27,063. According to the SEC filing, these sales occurred on December 2, 2024, and were made to cover withholding tax obligations related to the vesting of restricted stock units (RSUs). The transaction comes as Pulmonx, currently valued at $258 million, is showing strong year-over-year revenue growth of 22%. InvestingPro analysis indicates that the stock is currently undervalued, with a robust financial health rating of “GOOD”.
Transactions included the sale of 392 shares at $6.19 per share, for a total of $2,426, and 690 shares at $6.18 per share, for a total of $4,264. In addition, Beran sold 1,756 shares at $6.19 per share, amounting to $10,869, and 1,538 shares at $6.18 per share, for a total of $9,504.
Following these transactions, Beran retains direct ownership of 291,057 shares of Pulmonx Corp. The company’s shares are traded on NASDAQ under the symbol LUNG.
In other recent news, Pulmonx Corporation reported strong third-quarter results, highlighted by a 15% year-over-year increase in worldwide sales totaling $20.4 million. The US market played a significant role, with revenue growth of 17%, while international sales also saw growth of 12%. The company reaffirmed its full-year revenue guidance, pointing to a strategic focus on physician training, patient workflow automation and awareness of its Zephyr valves for the treatment of COPD.
Pulmonx reported a net loss of $14.1 million for the quarter, despite a slight year-over-year improvement. However, the company was able to reduce its operating expenses by approximately $5 million, maintaining a stable gross margin of 74%. The company has also made significant progress in its clinical trials, with the AeriSeal program set for commercial launch outside the US in 2026 and within the US in 2027.
These recent developments reflect Pulmonx’s resilience and strategic foresight. The company’s management remains optimistic about future growth, especially in international markets, including China and Europe. As Pulmonx continues to execute on its growth strategies, the market will be closely watching its next moves, especially with the expected commercial launch of its AeriSeal program.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
